Wednesday 9 January, 2008

regulatory approvals to Clinical Pharmacology unit of GVK Bioscience

The Clinical Pharmacology Unit of GVK Biosciences has received approvals from regulatory bodies such as US FDA, AFSAAPS, WHO and ANVISA. The approvals open up global markets to GVK BIO's clients in the US, Europe and Latin American countries in addition to the domestic sector.Manni Kantipudi, president of GVK Bio stated, "The approvals validate GVK BIO's high quality systems and practices".As a first step, GVK Bio has expanded and built a new state-of-the-art Bioanalytical facility in addition to the existing one to cater to the growing business demands. GVK Bio is also setting up its own Clinical Laboratory and aims for an early accreditation."GVK BIO aims to be a full service Clinical Research Organization offering services from BA/BE to phase I through phase IV Clinical Trials", said Mr. G V Sanjay Reddy, managing director, GVK Bio.

No comments:

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker